Kymera Investor Presentation Deck
June 2023, 60 slides
  1. Kymera
  2. Related Decks
  3. Investor Presentation Decks
inventing new medicines | Kymera
forward looking statements | Kymera
overview key accomplishments | Kymera
differentiated approach to | Kymera
what our recent accomplishments mean for and | Kymera
building franchises in immunology and oncology in diseases with large unmet needs and commercial opportunities | Kymera
pipeline of novel protein degraders | Kymera
objectives a a | Kymera
| Kymera
degrading best approach to block driven inflammation on | Kymera
degrader best in class potential in immune inflammation | Kymera
phase trial design and summary | Kymera
key phase accomplishments | Kymera
disease characteristics | Kymera
patient disposition total | Kymera
plasma and degradation in and patients dosed for days is comparable to | Kymera
reduced in skin lesions of and patients on day to at least same level as healthy subjects | Kymera
up to inhibition of disease relevant in both and patients | Kymera
in inhibition of disease relevant plasma and acute phase reactants by in patients | Kymera
disease relevant genes in skin lesions in of evaluable and patients at day | Kymera
significant reduction in score and pruritus | Kymera
investigator global assessment viga | Kymera
case study patient | Kymera
showed meaningful signs of clinical activity in comparing favorably to placebo and soc | Kymera
significant reductions in an counts leading to responses | Kymera
significant reductions in pain pruritus | Kymera
physician global assessment | Kymera
case study patient | Kymera
case study patient a | Kymera
showed meaningful signs of clinical activity in comparing favorably to placebo and soc | Kymera
adverse events related to study drug occurring in patient | Kymera
prolongation spontaneously resolves to by day | Kymera
part summary | Kymera
| Kymera
are potent degraders of and substrates targeting redundant pro survival pathways in | Kymera
highly active on intermittent dosing in preclinical models | Kymera
phase dose and expansion trials to evaluate in patients with | Kymera
plasma showing dose proportional increase in exposure | Kymera
and degradation profile of and consistent with strong activity in preclinical models | Kymera
desired translation of and safety of | Kymera
| Kymera
degraders in oncology | Kymera
highly active on intermittent dosing regimens | Kymera
phase dose and expansion trial to evaluate in adult patients with and solid tumors | Kymera
overall safety | Kymera
consistent plasma across the evaluated dose levels | Kymera
strong proof of mechanism for with up to mean maximum nearing desired degradation profile at | Kymera
achieved pathway inhibition and of inflammatory in blood a a a a etna | Kymera
desired translation of and safety of | Kymera
| Kymera
degraders in oncology | Kymera
degradation not inhibition efficiently restores | Kymera
degrader investigational drug is superior to small molecule inhibitors | Kymera
single dose of leads to sustained tumor regression and is superior to small molecule inhibitors | Kymera
potently degrades and the pathway in preclinical leukemia models tates a sell smell | Kymera
strong single agent and combinatorial activity in resistant models | Kymera
phase dose and expansion trial to evaluate in adult patients with liquid and solid tumors | Kymera
first degrader in clinic | Kymera
well positioned for continued success is executing on its mission to build a fully integrated global company as a recognized leader in our industry leading productivity has produced clinical programs and a deep and innovative pipeline of valuable high impact programs we have demonstrated and safety in phase trials that validate our platform molecule design and target selection capabilities and strategies we are well capitalized with an experienced team that is highly focused we are only at the beginning of our journey as knowledge experience and drive positions us to maximize the untapped potential of in areas with large clinical and commercial opportunities | Kymera
thank you | Kymera
See More
Kymera
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Tumor
Plasma
Blood
Solid tumor
Recent decks by Kymera
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Results
December 2022
See all presentations by Kymera (7 decks)
Related decks
RenovoRx
IPO
August 2021
Relay Therapeutics
IPO
July 2020
Immatics
Investor Presentation
November 2023
Nuvalent
Investor Presentation
May 2023
Immix Biopharma
Investor Presentation
January 2024
BioNTech
Results
August 2021
Immix Biopharma
Investor Presentation
November 2023
Recursion Pharmaceuticals
Investor Day
January 2023
Recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Results
December 2022
RenovoRx
IPO
August 2021
Relay Therapeutics
IPO
July 2020
Immatics
Investor Presentation
November 2023
Nuvalent
Investor Presentation
May 2023
Immix Biopharma
Investor Presentation
January 2024
BioNTech
Results
August 2021
Immix Biopharma
Investor Presentation
November 2023
Recursion Pharmaceuticals
Investor Day
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights